Toxicities will be graded using the NCI CTCAE Version 4.03. Efficacy: ORR and PFS will be assessed by CT or MRI of target and non -target lesions every 8 weeks and will be evaluated according to RECIST Version 1.1 and irRC. OS, DOR , and DCR will also be assessed. An assessment of pancreatic cancer symptoms will be conducted via PROs using the Functional Assessment of Cancer Therapy (FACT) Hepatobil iary Symptom Index-8 (FHSI-8) instrument on study day 1, every 28 days thereafter, and at the day 28 foll ow-up visit. Exploratory Analysis: Molecular Profiling and Analysis: Genomic sequencing of tumor cells from tissue relative to non -tumor cells from whole blood will be profiled to identify the genomic variances that may contribute to response or disease progression and provide an understanding of molecular abnormalities.